By Sabela Ojea
Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements.
Shares rose 9.2% to $7.81 in post-market trading. Through Wednesday's close, the stock has fallen 85% over the past 12 months.
The clinical-stage biotechnology company on Wednesday said that it hired MTS Health Partners as financial adviser for its strategic evaluation process.
"Given the positive data and commercial potential with this [company] pipeline, as well as the clearance from the Food and Drug Administration on the lead program's pivotal study, we believe this is a rare opportunity for a partner," Chief Executive Stephen Brady said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 09, 2025 17:01 ET (21:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。